Matches in SemOpenAlex for { <https://semopenalex.org/work/W3142226530> ?p ?o ?g. }
- W3142226530 endingPage "1766" @default.
- W3142226530 startingPage "1766" @default.
- W3142226530 abstract "Chronic lymphocytic leukemia (CLL) is characterized by progressive immunosuppression and diminished cancer immunosurveillance. Immune checkpoint blockade (ICB)-based therapies, a major breakthrough against cancer, have emerged as a powerful tool to reinvigorate antitumor responses. Herein, we analyzed the role of the novel inhibitory checkpoint BTLA and its ligand, HVEM, in the regulation of leukemic and natural killer (NK) cells in CLL. Flow cytometry analyses showed that BTLA expression is upregulated on leukemic cells and NK cells from patients with CLL, whereas HVEM is downregulated only in leukemic cells, especially in patients with advanced Rai-Binet stage. In silico analysis revealed that increased HVEM, but not BTLA, mRNA expression in leukemic cells correlated with diminished overall survival. Further, soluble BTLA (sBTLA) was found to be increased in the sera of patients with CLL and highly correlated with poor prognostic markers and shorter time to treatment. BTLA blockade with an anti-BTLA monoclonal antibody depleted leukemic cells and boosted NK cell-mediated responses ex vivo by increasing their IFN-γ production, cytotoxic capability, and antibody-dependent cytotoxicity (ADCC). In agreement with an inhibitory role of BTLA in NK cells, surface BTLA expression on NK cells was associated with poor outcome in patients with CLL. Overall, this study is the first to bring to light a role of BTLA/HVEM in the suppression of NK cell-mediated immune responses in CLL and its impact on patient’s prognosis, suggesting that BTLA/HVEM axis may be a potential therapeutic target in this disease." @default.
- W3142226530 created "2021-04-13" @default.
- W3142226530 creator A5033968461 @default.
- W3142226530 creator A5045769320 @default.
- W3142226530 creator A5062126850 @default.
- W3142226530 creator A5069586781 @default.
- W3142226530 creator A5071261900 @default.
- W3142226530 creator A5078500466 @default.
- W3142226530 creator A5085368557 @default.
- W3142226530 date "2021-04-07" @default.
- W3142226530 modified "2023-10-02" @default.
- W3142226530 title "BTLA/HVEM Axis Induces NK Cell Immunosuppression and Poor Outcome in Chronic Lymphocytic Leukemia" @default.
- W3142226530 cites W1480075263 @default.
- W3142226530 cites W1983622643 @default.
- W3142226530 cites W1985499930 @default.
- W3142226530 cites W1986976471 @default.
- W3142226530 cites W1996416214 @default.
- W3142226530 cites W2006608981 @default.
- W3142226530 cites W2022054497 @default.
- W3142226530 cites W2023505492 @default.
- W3142226530 cites W2028971492 @default.
- W3142226530 cites W2036043979 @default.
- W3142226530 cites W2054499416 @default.
- W3142226530 cites W2057686471 @default.
- W3142226530 cites W2062956658 @default.
- W3142226530 cites W2067064694 @default.
- W3142226530 cites W2075736621 @default.
- W3142226530 cites W2095491662 @default.
- W3142226530 cites W2105660843 @default.
- W3142226530 cites W2116057181 @default.
- W3142226530 cites W2134667174 @default.
- W3142226530 cites W2135215267 @default.
- W3142226530 cites W2135216058 @default.
- W3142226530 cites W2147132132 @default.
- W3142226530 cites W2147605136 @default.
- W3142226530 cites W2147615186 @default.
- W3142226530 cites W2153289530 @default.
- W3142226530 cites W2154553633 @default.
- W3142226530 cites W2475414235 @default.
- W3142226530 cites W2515527586 @default.
- W3142226530 cites W2553763399 @default.
- W3142226530 cites W2558290791 @default.
- W3142226530 cites W2588504055 @default.
- W3142226530 cites W2589987575 @default.
- W3142226530 cites W2605683323 @default.
- W3142226530 cites W2615164318 @default.
- W3142226530 cites W2735707423 @default.
- W3142226530 cites W2748446253 @default.
- W3142226530 cites W2780673440 @default.
- W3142226530 cites W2781801165 @default.
- W3142226530 cites W2782684820 @default.
- W3142226530 cites W2785976742 @default.
- W3142226530 cites W2787624638 @default.
- W3142226530 cites W2790385276 @default.
- W3142226530 cites W2800170673 @default.
- W3142226530 cites W2802129756 @default.
- W3142226530 cites W2883679391 @default.
- W3142226530 cites W2894023013 @default.
- W3142226530 cites W2903630447 @default.
- W3142226530 cites W2907544179 @default.
- W3142226530 cites W2912986834 @default.
- W3142226530 cites W2915642235 @default.
- W3142226530 cites W2917158435 @default.
- W3142226530 cites W2924097878 @default.
- W3142226530 cites W2946657092 @default.
- W3142226530 cites W2952790890 @default.
- W3142226530 cites W2953257605 @default.
- W3142226530 cites W2960943033 @default.
- W3142226530 cites W2969466301 @default.
- W3142226530 cites W2971728187 @default.
- W3142226530 cites W2975035850 @default.
- W3142226530 cites W2975733352 @default.
- W3142226530 cites W2977253903 @default.
- W3142226530 cites W2990157180 @default.
- W3142226530 cites W2990580533 @default.
- W3142226530 cites W2991016171 @default.
- W3142226530 cites W2993255638 @default.
- W3142226530 cites W3000110301 @default.
- W3142226530 cites W3006483160 @default.
- W3142226530 cites W3007848523 @default.
- W3142226530 cites W3016167298 @default.
- W3142226530 cites W3028560143 @default.
- W3142226530 cites W3045510702 @default.
- W3142226530 cites W3085128374 @default.
- W3142226530 cites W3102450721 @default.
- W3142226530 cites W3109168993 @default.
- W3142226530 cites W3137521045 @default.
- W3142226530 cites W4242818520 @default.
- W3142226530 doi "https://doi.org/10.3390/cancers13081766" @default.
- W3142226530 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8067870" @default.
- W3142226530 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33917094" @default.
- W3142226530 hasPublicationYear "2021" @default.
- W3142226530 type Work @default.
- W3142226530 sameAs 3142226530 @default.
- W3142226530 citedByCount "19" @default.
- W3142226530 countsByYear W31422265302021 @default.
- W3142226530 countsByYear W31422265302022 @default.
- W3142226530 countsByYear W31422265302023 @default.